gw786034
Refractory Pediatric Solid Tumor
Samsung Medical CenterPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Refractory Pediatric Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Malika Kapadia | Phase 2 | BB |
Ifosfamide Samsung Medical Center | Phase 2 | B |
Carboplatin Samsung Medical Center | Phase 2 | B |
Ipilimumab Children's National Research Institute | Phase 2 | B |
Panobinostat Samsung Medical Center | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
gw786034 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →